Loading organizations...
BigOmics Analytics is a Ticino, Switzerland-based bioinformatics software company that develops cloud-based platforms enabling biologists to analyze and visualize complex omics data without coding expertise. The company operates a software-as-a-service model, providing enterprise and academic subscription licenses for its flagship Omics Playground platform to accelerate drug development and precision medicine research. The startup scaled its commercial operations by securing a CHF 2.7 million Pre-Series A funding round in 2024, building upon previous seed capital, and has recorded over 5,000 users visiting its platform in a single quarter. BigOmics Analytics is backed by institutional investors including TiVenture, Century Oak Capital, and Acequia Capital, and has established strategic commercial partnerships with entities like BC Platforms. The enterprise was founded in 2018 by Murodzhon Akhmedov and Ivo Kwee as a spin-off from the Institute of Oncology Research.
BigOmics has raised $2.4M across 2 funding rounds.
BigOmics has raised $2.4M in total across 2 funding rounds.
BigOmics Analytics is a Swiss biodata analytics startup founded in 2018, specializing in user-friendly platforms that enable biologists to visualize, analyze, and interpret complex omics data like RNA-seq, proteomics, and multi-omics datasets[1][2][3][5]. Its flagship product, Omics Playground, serves life scientists in academia, biotech, and pharma by simplifying data analysis from weeks to minutes, reducing R&D costs, and accelerating discoveries in precision medicine, cancer research, neurodegenerative diseases, and immunology[1][3][5][6]. The company supports over 6,000 researchers globally, with 60+ enterprise clients, and has raised 2.7M CHF (including a recent USD 1.6M round) to expand its tools and market reach[2][4].
BigOmics Analytics emerged as a 2018 spin-off from the Institute of Oncology Research (IOR) and Institute for Research in Biomedicine (IRB), both affiliated with the University of Italian Switzerland (USI) in Ticino, Lugano[2]. Co-founders Ivo Kwee (CTO) and Murodzhon (Murat) Akhmedov (CEO), leveraging their expertise in bioinformatics and biology, launched the first product, Omics Playground, in 2019 to address the pain of cumbersome omics analysis tools[2][4][5]. Early traction came quickly: by 2021, it secured 2.7M CHF in funding and enterprise clients, growing to support 1,500+ scientists; a 2025 USD 1.6M round from Diffusion Capital Partners, SICTIC angels, and TiVentures validated its momentum amid surging omics data volumes[2][4].
BigOmics rides the omics data explosion in precision medicine, where genomics, proteomics, and multi-omics generate vast datasets but overwhelm traditional tools, slowing breakthroughs in cancer, immunology, and neurodegeneration[4][5]. Timing is ideal amid AI-driven biotech booms and post-2020 data surges, with market forces like rising R&D costs (addressed via 82% time savings) and demand for reproducible, collaborative platforms favoring accessible solutions over expert-only software[1][6]. It influences the ecosystem by democratizing analysis for 6,000+ researchers, bridging academia-industry gaps, and enabling faster insights—positioning Switzerland's Ticino as a biodata hub while challenging fragmented tools from incumbents[2][4].
BigOmics is poised to dominate omics analytics as a "go-to platform," fueled by its latest USD 1.6M raise for product acceleration, new markets, and AI enhancements to handle real-time multi-omics[4]. Trends like exploding public datasets, immuno-oncology needs, and precision medicine mandates will propel growth, potentially expanding to 100k+ users and deeper pharma integrations. Its influence may evolve from startup disruptor to infrastructure standard, empowering labs worldwide to cut discovery timelines and drive cures—fast-tracking the data-driven biology revolution that began in a Swiss research institute.
BigOmics has raised $2.4M in total across 2 funding rounds.
BigOmics's investors include Lorenzo Leoni, Marc Jalabert, Nathan Kaiser, Raul Vejar, Acequia Capital, Century Oak Capital, Champion Hill Ventures, Draper Associates, Kima Ventures, KRM Interests LLC, Magical Capital.
BigOmics has raised $2.4M across 2 funding rounds. Most recently, it raised $1.4M Pre-Series A in December 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 10, 2021 | $1.4M Seed Plus | Lorenzo Leoni | Marc Jalabert, Nathan Kaiser, Raul Vejar, Acequia Capital, Century OAK Capital, Champion Hill Ventures | Announced |
| Sep 1, 2021 | $1M Seed | — | Draper Associates, Kima Ventures, KRM Interests LLC, Magical Capital | Announced |